L3VLUP
ProSign in

BNTX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BNTXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BNTX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterBNTXGILD
Q3 20204 holders, $504m25 holders, $14.2bn
Q4 20203 holders, $142m27 holders, $13.4bn
Q1 20214 holders, $993m24 holders, $14.5bn
Q2 202110 holders, $3.9bn18 holders, $14.9bn
Q3 202112 holders, $4.2bn20 holders, $16.4bn
Q4 20219 holders, $3.1bn20 holders, $16.8bn
Q1 202210 holders, $1.9bn28 holders, $13.2bn
Q2 202211 holders, $1.8bn26 holders, $13.6bn
Q3 20228 holders, $1.8bn24 holders, $13.3bn
Q4 202213 holders, $2.3bn32 holders, $21.1bn
Q1 20238 holders, $1.6bn27 holders, $21.8bn
Q2 202310 holders, $1.2bn24 holders, $20.7bn
Q3 20239 holders, $1.2bn24 holders, $20.0bn
Q4 20239 holders, $1.1bn22 holders, $21.5bn
Q1 20247 holders, $975m30 holders, $20.3bn
Q2 20249 holders, $877m28 holders, $18.5bn
Q3 202410 holders, $2.0bn29 holders, $24.2bn
Q4 20248 holders, $2.0bn28 holders, $25.9bn
Q1 20259 holders, $1.6bn33 holders, $32.0bn
Q2 20256 holders, $1.9bn27 holders, $30.9bn
Q3 20254 holders, $1.7bn23 holders, $29.4bn
Q4 20258 holders, $1.2bn25 holders, $34.3bn
Q1 20266 holders, $528m25 holders, $38.5bn
Q2 20269 holders, $1.3bn26 holders, $34.2bn
BNTX

Biontech Se

Holders
9
Reported value
$1.6bn
Buyers
4
Sellers
5

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
33
Reported value
$32.0bn
Buyers
21
Sellers
12

Breadth +9 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BNTX (3)

Baillie Gifford & Co, Squarepoint Ops LLC, Viking Global Investors LP

Only GILD (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, ExodusPoint Capital Management LP, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →